As of 2025-09-18, the Intrinsic Value of Eupraxia Pharmaceuticals Inc (EPRX.TO) is -3.65 CAD. This EPRX.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 7.39 CAD, the upside of Eupraxia Pharmaceuticals Inc is -149.34%.
Based on its market price of 7.39 CAD and our intrinsic valuation, Eupraxia Pharmaceuticals Inc (EPRX.TO) is overvalued by 149.34%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.65 - -3.65 | -3.65 | -149.34% |
| DDM - Stable | (5.41) - (12.93) | (9.17) | -224.1% |
| DDM - Multi | (0.19) - (0.35) | (0.25) | -103.3% |
| Market Cap (mil) | 265.74 |
| Beta | 0.89 |
| Outstanding shares (mil) | 35.96 |
| Enterprise Value (mil) | 238.29 |
| Market risk premium | 5.10% |
| Cost of Equity | 11.25% |
| Cost of Debt | 5.00% |
| WACC | 7.47% |